Meridian Wealth Management’s GSK GSK Stock Holding History

Meridian Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$416K	Buy	7,928 +1,668	+27%	+$88.2K	0.01%	593
2026 Q1	$345K	Sell	6,260 -60	-0.9%	-$3.25K	0.01%	616
2025 Q4	$310K	Buy	6,320 +20	+0.3%	+$933	0.01%	609
2025 Q3	$272K	Sell	6,300 -176	-3%	-$6.88K	0.01%	603
2025 Q2	$249K	Buy	6,476 +305	+5%	+$11.7K	0.01%	594
2025 Q1	$239K	Sell	6,171 -5,210	-46%	-$191K	0.01%	565
2024 Q4	$385K	Sell	11,381 -2,255	-17%	-$81.2K	0.02%	473
2024 Q3	$557K	Sell	13,636 -2,380	-15%	-$97.4K	0.03%	390
2024 Q2	$617K	Buy	+16,016	New	+$674K	0.07%	156
2024 Q1	–	Sell	-44,686	Closed	-$1.66M	–	331
2023 Q4	$1.66M	Buy	44,686 +38,211	+590%	+$1.37M	0.11%	188
2023 Q3	$235K	Sell	6,475 -1,704	-21%	-$60.5K	0.01%	490
2023 Q2	$292K	Sell	8,179 -320	-4%	-$11.5K	0.02%	445
2023 Q1	$302K	Sell	8,499 -7	-0.1%	-$245	0.03%	420
2022 Q4	$299K	Buy	+8,506	New	+$283K	0.03%	414
2022 Q3	–	Sell	-9,298	Closed	-$506K	–	523
2022 Q2	$506K	Buy	9,298 +3,252	+54%	+$180K	0.04%	344
2022 Q1	$329K	Hold	6,046	–	–	0.04%	297
2021 Q4	$333K	Buy	6,046 +320	+6%	+$16.6K	0.04%	303
2021 Q3	$274K	Buy	5,726 +467	+9%	+$23.5K	0.03%	325
2021 Q2	$262K	Buy	+5,259	New	+$253K	0.03%	322
2019 Q3	–	Sell	-1,040	Closed	-$52K	–	300
2019 Q2	$52K	Buy	+1,040	New	+$52.2K	0.02%	365

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Meridian Wealth Management's GSK Position: Q2 2026 in Review

Meridian Wealth Management increased its GSK (GSK) stake by 27% in Q2 2026, buying an estimated $88.2K and bringing the position to 7,928 shares worth $416K. The position accounts for 0.01% of the portfolio, ranked #593.

Meridian Wealth Management first reported a position in GSK in Q2 2019 and has held it in 20 quarters since. The position peaked at $1.66M in Q4 2023. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Meridian Wealth Management held 7,928 shares of GSK worth $416K as of Q2 2026.
Meridian Wealth Management bought 1,668 GSK shares in Q2 2026, an estimated $88.2K.
GSK made up 0.01% of Meridian Wealth Management's portfolio in Q2 2026, its #593 holding.
Meridian Wealth Management first reported a position in GSK in Q2 2019 and has held it in 20 quarters since.
Meridian Wealth Management's GSK position peaked at $1.66M in Q4 2023.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Meridian Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.